Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
Donepezil Hydrochloride Tablet
Product Images NDC 71335-2436
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-2436). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
This is a chart showing the cumulative percentage of patients for two groups - one group taking Donepezil Hydrochloride 10 mg/day and another group taking a placebo. It also shows the change in ADCS-ADL from baseline for the patients in both groups.*
Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
This text provides information on the change from baseline in the least squares mean (LS mean) for Clinical Improvement and Clinical Decline during weeks of drug treatment with Donepezil Hydrochloride at 23 mg/day and 10 mg/day. The data indicates the impact of the drug treatment on clinical outcomes over time.*
Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
This text appears to be a medication administration schedule for Donepezil Hydrochloride, with doses of 23 mg/day and 10 mg/day. It also includes a rating scale for assessing improvement or worsening in symptoms using the CIBIC-plus Rating scale.*
Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
This text provides information on the ADAS-cog changes from the baseline in relation to different drug treatments. It mentions the administration of Donepezil Hydrochloride at doses of 10 mg/day and 4 mg/day compared to a placebo, for determining clinical improvement or decline. The study also seems to explore the effects of drug treatment over weeks.*
Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
This text provides a brief overview of the percentage of patients in a study comparing the effects of Donepezil Hydrochloride at different doses with a placebo. The text includes a scale from "Markedly Improved" to "Worse" in terms of patient changes and mentions the CIBIC-plus Rating. The data presented seems to be related to evaluating the efficacy and impact of different dosages of Donepezil Hydrochloride in patients.*
Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
This text provides information on the change from baseline in clinical improvement over 3 months of drug treatment with Donepezil Hydrochloride 10 mg/day compared to placebo. The mean values are presented along with standard error.*
Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
Cumulative Percentage of Patients graph displaying the change from baseline in SIB score after treatment with Donepezil Hydrochloride 10 mg/day and placebo. The graph represents data points at 5%, 15%, 30%, 45%, 50%, 75%, and 100%. It shows the distribution of patients and the impact of the different treatments on SIB score.*
Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
This text appears to be a chart showing the mean change from baseline in ADL (Activities of Daily Living) scores for individuals taking Donepezil Hydrochloride 10 mg/day compared to those taking a Placebo over a period of 3 months of drug treatment. The chart likely indicates the clinical improvement associated with Donepezil Hydrochloride in ADL scores.*
Chemical Structure (Donepezil Str)
Label (Lbl713352436)
Each tablet contains Donepezil Hydrochloride USP 10 mg. Store at 20° to 25° C (68° to 77° F); excursions permitted to 15° to 30° C (59° to 86° F). Dispense in tight containers. Recommended dosage: See full prescribing information at www.dailymed.nlm.nih.gov. This product is repackaged by Bryant Ranch Prepack, Inc. for ACI Healthcare.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
